Scienture Inks Exclusive Distribution Deal for REZENOPY Across 2,000 Addiction Treatment Centers
SCNX sits 31% above its 52-week low of $0.238 on light trading volume (0.2× avg).
Summary
Scienture has signed an exclusive Sales, Marketing and Distribution Agreement with an unnamed partner to place REZENOPY, its high-dose naloxone nasal spray, into approximately 2,000 opioid treatment program clinics and addiction treatment centers nationwide. This is the first dedicated channel into the addiction treatment market, complementing existing wholesale and GPO efforts. The company cites IQVIA data showing a $140 million U.S. naloxone market, underscoring the commercial opportunity. The deal expands REZENOPY's reach beyond the initial launch in August and could become a meaningful revenue contributor as adoption builds. Watch for the partner's identity and any initial purchase commitments in future filings.
At the time of this announcement, SCNX was trading at $0.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $0.24 to $2.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.